Dr. Reddy's Laboratories Limited (NYSE: RDY ) is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased revenue from new products within the high-growth segments like biosimilars and GLP-1. I believeI am a value focused investor, conducting fundamental research on sectors like but not limited to chemicals, homebuilders, building materials, industrials and metals & mining. I prefer to invest in stocks which are cheaply available and have a catalyst in the nea ...